home > news > detailed info

TP3 global presents innovative thermal protection at cool chain 2018 london, uk

TP3 Global, a leading supplier of thermal packaging solutions for the pharmaceutical industry, is to showcase its newly-released range of thermal covers at the 17th annual Cool Chain conference in January 2018.

The SilverQuilt cover, which was launched in November 2017, provides superior protection for valuable, sensitive cargo, such as controlled room-temperature pharmaceuticals that must be kept within a temperature range of 15 to 25°C in extreme profiles.

TP3 will also feature the innovative PalletQuilt from TP3’s US partner, Q Sales and Products. This is a reusable solution that is supplied in a compressed format, enabling huge cost savings on shipping and storage.

Visitors to the stand will be able to review the covers and learn more about TP3 Global’s new, state-of-the-art technical centre, which allows the UK-based company to undertake all aspects of testing & qualifications to recognised industrial standards, both for its own covers, and those of its customers.

Members of TP3 Global’s technical team will be available at the stand on the 30th and 31st of January, including: Dharmesh Chauhan, Commercial Director; Shane O’Shaughnessy, VP, Global Accounts; Kevin Valentine, Chief Technical Officer; and Paddy O’Hara, Packaging Technologist. Paul Yardon and Jim O’Donnell from TP3’s US partner, QPS, will also attend.

Dharmesh Chauhan, Commercial Director of TP3 Global, said:

“We’ve been supporters of the Cool Chain conference for a number of years now. The event has always been a fantastic way of building connections within the industry and making sure we are aligned with industry developments.

“For 2018’s event, we’ll be focusing largely on the SilverQuilt and PalletQuilt products, and how customers can benefit from our leading technical centre to ensure a qualified, risk-based approach to Good Distribution Practices.

“We also look forward to discussing industry standards – particularly those surrounding R-values, which is a topic we focused on in 2017. It’s our hope that, by continuing the conversation, we can facilitate the development of some concrete, international standards, which would be to everyone’s benefit.

“Our team will be on hand at stand 1 by the entrance, and we look forward to welcoming global delegates to what should be a varied and thought-provoking event.”

For more information on TP3 Global and its thermal packaging solutions, please visit:


Press enquiries to:
Tom Leatherbarrow / Nicole Laffan
WPR – +44 (0) 121 456 3004 /

Notes to Editors:
TP3 Global is a world leader in the development, manufacture and supply of thermal protection systems for temperature-sensitive palletised loads. Accredited to both ISO 9001 and ISO 14001, the company operates from locations in Europe, the Americas, Asia and Australia, serving a global customer base including major pharmaceutical manufacturers.

A pioneer in materials technology, TP3 Global manufactures a full range of single use or re-usable covers and liners for pallets, air cargo, cartons or drums.

Print this page
Send to a friend
News and Press Releases

Biologics Day

On 20. July 2018, Phenomenex and SCIEX will co-host a full day of seminars, providing solutions for Biologics. The series of mini-seminars presented by technical experts from both companies, will cover methods for characterisation and QC testing, troubleshooting and new trends in analysis for this industry.  
More info >>

White Papers

Recommendations for Implementing Assessment Criteria Guidelines in Lymphoma and Chronic Lymphocytic Leukemia Clinical Trials

Perceptive Informatics

Standardized assessment criteria are becoming increasingly important in obtaining valid outcomes in oncology clinical trials. While standardized criteria encourage a more uniform approach to assessing clinical trial data, they are often subject to the interpretation of the user. These differences in interpretation, while seemingly minor, can have a major impact on assessments. The most commonly used standardized criteria for lymphoma have been no exception. Differences such as minimum new lesion size, lymph node normalization size requirements, inclusion of extranodal lesions and assessment of organomegaly can have a profound effect on overall response. Additionally, heightened scrutiny of the assessment criteria used in a given protocol can lead to questions about a drug’s efficacy if not applied correctly according to regulators’ interpretation.
More info >>

Industry Events

SMi’s 5th Molecular Diagnostics Conference

9-11 July 2018, Holiday Inn Kensington Forum, London, UK

SMi is proud to announce their 5th Molecular Diagnostics conference. The event will take place in central London on Monday 9th and Tuesday 10th July 2018, along with two half-day post-conference workshops taking place on Wednesday 11th July 2018
More info >>

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement